Kinome profiling reveals pathogenic variant specific protein signalling networks in MEN2 children with Medullary

B Rix1,2, R Chauhan2, Z Masoumi1

  • 1ProteoStem Lab, Centre for Blood Research, York Biomedical Research Institute, Department of Biology, University of York, York, UK.

PubMed

Insights

This study investigated the functional kinome in Multiple Endocrine Neoplasia Type 2 (MEN2) patients. Findings reveal subtype-specific signaling pathway alterations, identifying potential new therapeutic targets for MEN2.

Area of Science:

  • Oncology
  • Genetics
  • Molecular Biology

Background:

  • Multiple Endocrine Neoplasia Type 2 (MEN2) is an inherited disorder caused by RET gene mutations.
  • Tumor development in MEN2 is unpredictable, highlighting the need for deeper molecular understanding.
  • Current treatments lack curative options, emphasizing the need for novel therapeutic targets.

Purpose of the Study:

  • To investigate the functional kinome in familial MEN2 patients.
  • To identify MEN2 subtype and RET pathogenic variant-specific molecular alterations.
  • To uncover novel therapeutic targets for MEN2.

Main Methods:

  • Functional kinome profiling of 24 familial MEN2 patients.
  • Analysis of signaling pathways including mTOR, PKA, and NF-κB.
  • Validation of identified alterations in patient thyroid tissue.

Main Results:

  • Identified specific alterations in signaling pathways (mTOR, PKA, NF-κB, focal adhesions) linked to MEN2 subtypes and RET variants.
  • Demonstrated subtype and variant-specific molecular drivers of MEN2.
  • Validated these findings in patient thyroid tissues.

Conclusions:

  • The study uncovers novel, specific molecular drivers for MEN2 and its subtypes.
  • Identified potential new therapeutic targets for MEN2, advancing precision medicine.
  • Provides a foundation for developing targeted therapies beyond prophylactic thyroidectomy.

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
7.2K
Protein Networks02:26

Protein Networks

An organism can have thousands of different proteins, and these proteins must cooperate to ensure the health of an organism. Proteins bind to other proteins and form complexes to carry out their functions. Many proteins interact with multiple other proteins creating a complex network of protein interactions.
These interactions can be represented through maps depicting protein-protein interaction networks, represented as nodes and edges. Nodes are circles that are representative of a protein,...
3.9K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.3K